scPharmaceuticalsSCPH
SCPH
About: scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
Employees: 96
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2,977% more call options, than puts
Call options by funds: $400K | Put options by funds: $13K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
4% more funds holding
Funds holding: 85 [Q4 2024] → 88 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
6.11% less ownership
Funds ownership: 79.49% [Q4 2024] → 73.37% (-6.11%) [Q1 2025]
31% less capital invested
Capital invested by funds: $141M [Q4 2024] → $97M (-$43.8M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
204%
upside
Avg. target
$15
280%
upside
High target
$18
356%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Naz Rahman | 204%upside $12 | Buy Maintained | 20 Mar 2025 |
HC Wainwright & Co. Douglas Tsao | 356%upside $18 | Buy Reiterated | 20 Mar 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
3 weeks ago
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and cut down on hospital readmissions. Q1 seasonality is in the rearview mirror, with multiple tailwinds, including Medicare redesign and label expansion, to fuel growth going forward.
Neutral
Seeking Alpha
1 month ago
scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants William Thorpe - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good afternoon and welcome to scPharmaceuticals First Quarter 2025 Earnings Conference Call.
Negative
Zacks Investment Research
1 month ago
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.36 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Generated net FUROSCIX ® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14 th , at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
1 month ago
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET
Neutral
GlobeNewsWire
1 month ago
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences:
Neutral
Seeking Alpha
2 months ago
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call.
Negative
Zacks Investment Research
2 months ago
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million, and full year 2024 revenue of $36.3 million
Neutral
GlobeNewsWire
3 months ago
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET
Charts implemented using Lightweight Charts™